Boston Scientific Announces FDA Approval and First U.S. Implant of New Devices To Treat Bradycardia
Boston Scientific Corporation (NYSE: BSX) announces U.S. Food and Drug Administration (FDA) approval and market launch of its INGENIO™ and ADVANTIO™ pacemakers and INVIVE™ cardiac resynchronization therapy pacemakers (CRT-P).
The first implant of the INGENIO pacemaker in the U.S. was performed on May 3 by Bruce L. Wilkoff, M.D., Director of Cardiac Pacing and Tachyarrhythmia Devices at the Cleveland Clinic.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.